Literature DB >> 33611730

CYP2C19 Loss-of-Function Associated with First-Time Ischemic Stroke in Non-surgical Asymptomatic Carotid Artery Stenosis During Clopidogrel Therapy.

Pious D Patel1,2, Xinnan Niu3, Chevis N Shannon4,5, Joshua C Denny3,6, Josh F Peterson3,6, Matthew R Fusco4,5, Rohan V Chitale4,5.   

Abstract

This study measures effect of CYP2C19 genotype on ischemic stroke risk during clopidogrel therapy for asymptomatic, extracranial carotid stenosis patients. Using deidentified electronic health records, patients were selected for retrospective cohort using administrative code for carotid stenosis, availability of CYP2C19 genotype result, clopidogrel exposure, and established patient care. Patients with intracranial atherosclerosis, aneurysm, arteriovenous malformation, prior ischemic stroke, or observation time <1 month were excluded. Dual antiplatelet therapy patients were included. Patients with carotid endarterectomy or stenting were analyzed in a separate subgroup. Time-to-event analysis using Cox regression was conducted to model ischemic stroke events based on CYP2C19 loss-of-function allele and adjusted with the most predictive covariates from univariate analysis. Covariates included age, gender, race, length of aspirin, length of concurrent antiplatelet/anticoagulant treatment, diabetes, coagulopathy, hypertension, heart disease, atrial fibrillation, and lipid disorder. A total of 1110 patients met selection criteria for medical therapy cohort (median age 68 [interquartile range (IQR) 60-75] years, 64.9% male, 91.9% Caucasian). Median study period was 2.8 [0.8-5.3] years. A total of 47 patients (4.2%) had an ischemic stroke event during study period. CYP2C19 loss-of-function allele was strongly associated with ischemic stroke events (one allele: HR 2.3, 95% CI 1.1-4.7, p=0.020; two alleles: HR 10.2, 95% CI 2.8-36.8, p<0.001) after adjustment. For asymptomatic carotid stenosis patients receiving clopidogrel to prevent ischemic stroke, CYP2C19 loss-of-function allele is associated with 2- to 10-fold increased risk of ischemic stroke. CYP2C19 genotype may be considered when selecting antiplatelet therapy for stroke prophylaxis in non-procedural, asymptomatic carotid stenosis.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  CYP2C19; Carotid stenosis; Clopidogrel; Ischemic stroke; Pharmacogenetics

Mesh:

Substances:

Year:  2021        PMID: 33611730     DOI: 10.1007/s12975-021-00896-3

Source DB:  PubMed          Journal:  Transl Stroke Res        ISSN: 1868-4483            Impact factor:   6.829


  24 in total

1.  Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Paul Muntner; Alvaro Alonso; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Sandeep R Das; Francesca N Delling; Luc Djousse; Mitchell S V Elkind; Jane F Ferguson; Myriam Fornage; Lori Chaffin Jordan; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Tak W Kwan; Daniel T Lackland; Tené T Lewis; Judith H Lichtman; Chris T Longenecker; Matthew Shane Loop; Pamela L Lutsey; Seth S Martin; Kunihiro Matsushita; Andrew E Moran; Michael E Mussolino; Martin O'Flaherty; Ambarish Pandey; Amanda M Perak; Wayne D Rosamond; Gregory A Roth; Uchechukwu K A Sampson; Gary M Satou; Emily B Schroeder; Svati H Shah; Nicole L Spartano; Andrew Stokes; David L Tirschwell; Connie W Tsao; Mintu P Turakhia; Lisa B VanWagner; John T Wilkins; Sally S Wong; Salim S Virani
Journal:  Circulation       Date:  2019-03-05       Impact factor: 29.690

Review 2.  Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.

Authors:  Melissa D Klein; Craig R Lee; George A Stouffer
Journal:  Pharmacogenomics       Date:  2018-07-20       Impact factor: 2.533

3.  Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study.

Authors:  P L Kolominsky-Rabas; M Weber; O Gefeller; B Neundoerfer; P U Heuschmann
Journal:  Stroke       Date:  2001-12-01       Impact factor: 7.914

Review 4.  Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.

Authors:  Yuesong Pan; Weiqi Chen; Yun Xu; Xingyang Yi; Yan Han; Qingwu Yang; Xin Li; Li'an Huang; S Claiborne Johnston; Xingquan Zhao; Liping Liu; Qi Zhang; Guangyao Wang; Yongjun Wang; Yilong Wang
Journal:  Circulation       Date:  2016-11-02       Impact factor: 29.690

5.  Carotid artery stenosis as a cause of stroke.

Authors:  Matthew L Flaherty; Brett Kissela; Jane C Khoury; Kathleen Alwell; Charles J Moomaw; Daniel Woo; Pooja Khatri; Simona Ferioli; Opeolu Adeoye; Joseph P Broderick; Dawn Kleindorfer
Journal:  Neuroepidemiology       Date:  2012-10-11       Impact factor: 3.282

6.  Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.

Authors:  Yilong Wang; Xingquan Zhao; Jinxi Lin; Hao Li; S Claiborne Johnston; Yi Lin; Yuesong Pan; Liping Liu; David Wang; Chunxue Wang; Xia Meng; Jianfeng Xu; Yongjun Wang
Journal:  JAMA       Date:  2016-07-05       Impact factor: 56.272

7.  Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Authors:  S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2013-05-22       Impact factor: 6.875

8.  Influence of Cyp2c19*2 Gene Variant on Therapeutic Response During Clopidogrel Treatment in Patients with Carotid Artery Stenosis.

Authors:  Dragana Bačković; Svetlana Ignjatović; Ljiljana Rakićević; Jelena Kusić-Tišma; Dragica Radojković; Branko Čalija; Evgenija Strugarević; Ðorđe Radak; Mirjana Kovač
Journal:  J Med Biochem       Date:  2015-12-30       Impact factor: 3.402

9.  Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.

Authors:  Aleksi Tornio; Rob Flynn; Steve Morant; Elena Velten; Colin N A Palmer; Thomas M MacDonald; Alex S F Doney
Journal:  Clin Pharmacol Ther       Date:  2017-09-19       Impact factor: 6.875

Review 10.  Symptomatic Carotid Artery Stenosis: Surgery, Stenting, or Medical Therapy?

Authors:  Ashley M Wabnitz; Tanya N Turan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.